Pacific Edge Limited (ASX:PEB)

Market Cap	141.38M
Revenue (ttm)	15.99M
Net Income (ttm)	-30.29M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,544
Average Volume	20,166
Open	0.1400
Previous Close	0.1450
Day's Range	0.1300 - 0.1400
52-Week Range	0.0500 - 0.1900
Beta	0.94
RSI	39.77
Earnings Date	Nov 24, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PEB

Financial Performance

In 2024, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2023.

Financial numbers in NZD